There is existing evidence that the presence of a TP53 mutation may predict a worse prognosis in HCC, as it is associated with worse survival, a greater likelihood of disease recurrence, and more advanced stages of disease. The gene discussed is TP53; the disease is hepatocellular carcinoma.